Get the Stockscreener App
9.06
3.42%
0.30
Pre-market:
9.06
Immunome Inc stock is traded at $9.06, with a volume of 688.54K.
It is up +3.42% in the last 24 hours and up +2.37% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
See More
Previous Close:
$8.76
Open:
$8.84
24h Volume:
688.54K
Relative Volume:
0.63
Market Cap:
$788.31M
Revenue:
-
Net Income/Loss:
$-106.81M
P/E Ratio:
-2.7358
EPS:
-3.3117
Net Cash Flow:
$-8.40M
1W Performance:
+6.71%
1M Performance:
+2.37%
6M Performance:
-35.65%
1Y Performance:
-39.36%
1-Day Range:
$8.63
$9.24
1-Week Range:
$8.32
$9.24
52-Week Range:
$5.1501
$16.81
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
9.06 | 748.31M | 0 | -106.81M | -8.40M | -3.3117 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Lake Street | Buy |
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Apr-30-24 | Initiated | JP Morgan | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Jan-29-24 | Initiated | Leerink Partners | Outperform |
| Dec-19-23 | Initiated | Wedbush | Outperform |
| Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Two Sigma Investments LP Purchases Shares of 154,467 Immunome, Inc. (NASDAQ:IMNM) - Defense World
14,477 Shares in Immunome, Inc. (NASDAQ:IMNM) Acquired by ProShare Advisors LLC - Defense World
Millennium Management LLC Buys New Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
BNP Paribas Financial Markets Invests $70,000 in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Deutsche Bank AG Has $489,000 Stock Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet - MSN
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
(IMNM) Trading Report - news.stocktradersdaily.com
Immunome to Present at Upcoming Investor Conferences - BioSpace
Cancer Therapy Developer Immunome Set for TD Cowen and Goldman Sachs Healthcare Conferences - Stock Titan
Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Northern Trust Corp - Defense World
Immunome, Inc. Reports Q1 2025 Financial Results - TipRanks
Immunome stock rating cut to Hold by Boral Capital - Investing.com Nigeria
Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates - MSN
Leerink Partnrs Has Strong Estimate for Immunome Q2 Earnings - Defense World
Voya Investment Management LLC Has $166,000 Stock Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy - MSN
Immunome (NASDAQ:IMNM) Shares Gap Up Following Earnings Beat - Defense World
Immunome (IMNM) Financial Update and Clinical Progress in Q1 202 - GuruFocus
Wedbush Adjusts Price Target on Immunome to $21 From $33, Maintains Outperform Rating - marketscreener.com
(IMNM) Investment Report - news.stocktradersdaily.com
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update - BioSpace
Immunome Inc (IMNM) Q1 2025 Earnings: EPS Loss of $0.52 Beats Es - GuruFocus
Immunome Q1 Income From Operations USD -44.636 Million - marketscreener.com
Immunome Expands Share Reserve in Inducement Plan - TipRanks
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update | IMNM Stock News - GuruFocus
Raymond James Financial Inc. Makes New $274,000 Investment in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade - MSN
Immunome (IMNM) Expected to Announce Earnings on Tuesday - Defense World
MetLife Investment Management LLC Purchases 5,354 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome, Inc. (NASDAQ:IMNM) Shares Purchased by Wells Fargo & Company MN - Defense World
Invesco Ltd. Cuts Stock Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 - BioSpace
Brokerages Set Immunome, Inc. (NASDAQ:IMNM) Price Target at $25.33 - Defense World
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | IMNM Stock News - GuruFocus
(IMNM) Investment Analysis and Advice - news.stocktradersdaily.com
Taking on analysts’ expectations and winning: Immunome Inc (IMNM) - Sete News
Immunome Inc [IMNM] stock for 60,684 USD was acquired by BIENAIME JEAN JACQUES - knoxdaily.com
Legal & General Group Plc Sells 8,796 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):